Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Nayak AP, Lim JM, Arbel E, Wang R, Villalba DR, Nguyen TL, Schaible N, Krishnan R, Tang DD, Penn RB. Cooperativity between ß-agonists and c-Abl inhibitors in regulating airway smooth muscle relaxation. FASEB J. 2021 07; 35(7):e21674.
-
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018 02; 16(2):352-363.
-
Brailoiu GC, Deliu E, Barr JL, Console-Bram LM, Ciuciu AM, Abood ME, Unterwald EM, Brailoiu E. HIV Tat excites D1 receptor-like expressing neurons from rat nucleus accumbens. Drug Alcohol Depend. 2017 09 01; 178:7-14.
-
Karmaker A, Costanzo CM, Schwartz MZ. Is OM-3 synergistic with GLP-2 in intestinal failure? J Surg Res. 2017 01; 207:7-12.
-
Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget. 2016 Jul 26; 7(30):48280-48295.
-
Tao Y, Zhang X, Markovic-Plese S. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). J Neuroimmunol. 2016 09 15; 298:181-8.
-
Vasilevskaya IA, Selvakumaran M, Hierro LC, Goldstein SR, Winkler JD, O'Dwyer PJ. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res. 2015 Sep 15; 21(18):4143-52.
-
Nair DR, Monteiro JM, Memmi G, Thanassi J, Pucci M, Schwartzman J, Pinho MG, Cheung AL. Characterization of a novel small molecule that potentiates ß-lactam activity against gram-positive and gram-negative pathogens. Antimicrob Agents Chemother. 2015 Apr; 59(4):1876-85.
-
Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 1; 20(23):5956-63.
-
Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2092-103.